SCHEMBL116060

SCHEMBL116060

C#Cc1cnccc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 18/20 0.55
KDM6B O15054 8/20 0.55
KDM4D Q6B0I6 5/20 0.55
KDM4E B2RXH2 2/20 0.55
KDM4A O75164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 1/20 0.55
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
KMT2A Q03164 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
NAPRT Q6XQN6 1/20 0.40
APP P05067 1/20 0.39
GAA P10253 1/20 0.39
HCAR3 P49019 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8182630 0.86 KDM4C (0.48) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL2848389 0.82 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29952392 0.82 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL25309052 0.80 KDM4C (0.44) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL31019034 0.80 KDM4C (0.44) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL23826138 0.78 KDM4E (0.60) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL3711308 0.77 NPC1 (0.47) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29416303 0.76 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL71335 0.76 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL28151711 0.74 TDP1 (0.36) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424856-B1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2014-12-31 EP disclosed
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
EP-2424856-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2012-03-07 EP disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed
WO-2010125985-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 KDM4C 2026/4885KDM6B 4089/4885KDM4D 3638/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 KDM4C 2026/4885KDM6B 4089/4885KDM4D 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.